NICE verdict on Trodelvy threatens unequal access to drug in UK
In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK. The health technology assessment (HTA) agency said that while Trodelvy (sacituzumab govitecan) increases the time people have before their disease worsens and how […]